Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study*

Unknown

(2018)   JOURNAL OF MEDICAL VIROLOGY

96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects

(2015) Danielle P. Porter et al.   HIV CLINICAL TRIALS

HIV Drug Resistance Mutations in Proviral DNA from a Community Treatment Program

(2015) Anne Derache et al.   PLoS One

Antiretroviral Treatment of Adult HIV Infection

(2014) Huldrych F. Günthard et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Initiation of rilpivirine, tenofovir and emtricitabine (RPV/TDF/FTC) regimen in 363 patients with virological vigilance assessment in 'real life'

(2014) C. Amiel et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine

(2014) S. Gallien et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants

(2013) Frank J. Palella et al.   AIDS

96-week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials

(2013) Laurence Rimsky et al.   ANTIVIRAL THERAPY

Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz

(2013) A. M. Geretti et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

APOBEC3G-Induced Hypermutation of Human Immunodeficiency Virus Type-1 Is Typically a Discrete “All or Nothing” Phenomenon

(2012) Andrew E. Armitage et al.   PLoS Genetics

Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia

(2011) M. Wirden et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In-depth analysis of G-to-A hypermutation rate in HIV-1 env DNA induced by endogenous APOBEC3 proteins using massively parallel sequencing

(2010) Stefanie A. Knoepfel et al.   JOURNAL OF VIROLOGICAL METHODS

The Importance of Testing Genotypic Resistance in Proviral DNA of Patients Fully Responding to Highly Active Antiretroviral Therapy

(2009) Lucia Palmisano et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Analysis of the Percentage of Human Immunodeficiency Virus Type 1 Sequences That Are Hypermutated and Markers of Disease Progression in a Longitudinal Cohort, Including One Individual with a Partially Defective Vif

(2009) A. Piantadosi et al.   JOURNAL OF VIROLOGY

Conserved Footprints of APOBEC3G on Hypermutated Human Immunodeficiency Virus Type 1 and Human Endogenous Retrovirus HERV-K(HML2) Sequences

(2008) A. E. Armitage et al.   JOURNAL OF VIROLOGY